Covid 19 and Endocrinology

Diabetes plays a significant role in this phenotype because it is one of the most common comorbidities linked to COVID-19 severity and mortality. Careful management, including treatment changes, may be required to protect our patients from the most serious effects of COVID-19, whether they have diabetes or are hospitalised with COVID-19, as well as patients with SARS-CoV-2-induced recently onset diabetes. Obesity raises vulnerability to SARS-CoV-2 and the chance of a negative COVID-19 result.

    Related Conference of Covid 19 and Endocrinology

    April 10-11, 2025

    5th World Congress on Endocrine and Diabetes

    Dubai, UAE
    April 10-11, 2025

    4th International Summit on Hormonal Disorders

    Dubai, UAE
    May 08-09, 2025

    5th European Endocrinology and Diabetes Congress

    Madrid, Spain
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Paris, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    October 30-31, 2025

    5th Annual Summit on Diabetes and Endocrinology

    Paris, France
    November 06-07, 2025

    8th Annual Meeting on Diabetes and Endocrinology

    Dubai, UAE
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Paris, France

    Covid 19 and Endocrinology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in